StreetInsider.com News Articles

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Krognes Steve E.

Fri, 05 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260605/26611861.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Krognes Steve E.

Fri, 05 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260605/26611861.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Klein Peter S

Fri, 05 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260605/26611866.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Klein Peter S

Fri, 05 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260605/26611866.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: FLATLEY JAY T

Fri, 05 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260605/26611871.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: FLATLEY JAY T

Fri, 05 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260605/26611871.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Van Hauwermeiren Timothy

Fri, 05 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260605/26611847.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Van Hauwermeiren Timothy

Fri, 05 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260605/26611847.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Thornberry Nancy

Fri, 05 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260605/26611854.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Thornberry Nancy

Fri, 05 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260605/26611854.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Schenkein David P

Fri, 05 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260605/26611856.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Schenkein David P

Fri, 05 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260605/26611856.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Cook Jennifer E.

Fri, 05 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260605/26611830.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Cook Jennifer E.

Fri, 05 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260605/26611830.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: 667, L.P.

Fri, 05 Jun 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260605/26611474.html

Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: 667, L.P.

Fri, 05 Jun 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260605/26611474.html

Form 8-K Denali Therapeutics Inc. For: Jun 03

Thu, 04 Jun 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260604/26601837.html

Form 8-K Denali Therapeutics Inc. For: Jun 03

Thu, 04 Jun 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260604/26601837.html

Denali Therapeutics Inc. (DNLI) PT Lowered to $28 at Evercore ISI

Wed, 27 May 2026 13:47:12 -0400

Evercore ISI analyst Joshua Schimmer lowered the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $28.00 (from $31.00) while maintaining a Outperform rating.

Denali Therapeutics Inc. (DNLI) PT Lowered to $35 at Morgan Stanley

Tue, 26 May 2026 07:44:44 -0400

Morgan Stanley analyst Sean Laaman lowered the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $35.00 (from $40.00) while maintaining a Overweight rating.

Form 8-K Denali Therapeutics Inc. For: May 21

Fri, 22 May 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260522/26538052.html

Form 8-K Denali Therapeutics Inc. For: May 21

Fri, 22 May 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260522/26538052.html

Biogen and Denali discontinue Parkinson's drug after trial fails

Thu, 21 May 2026 18:00:13 -0400

Biogen Inc. (NASDAQ: BIIB) and Denali Therapeutics Inc. (NASDAQ: DNLI) announced that their experimental Parkinson's disease treatment BIIB122 failed to meet its primary and secondary endpoints in a Phase 2b clinical trial.

The LUMA study evaluated BIIB122, a small molecule inhibitor of LRRK2, in 648 individuals with early-stage Parkinson's disease. The drug did not slow disease progression compared to placebo when measured by the primary endpoint of Time to Confirmed Worsening in the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale.

Despite achieving over 90% kinase inhibition of peripheral LRRK2 and approximately 30% reduction in a biomarker of LRRK2 activity in

Biogen and Denali discontinue Parkinson's drug after trial fails

Thu, 21 May 2026 18:00:13 -0400

Despite achieving over 90% kinase inhibition of peripheral LRRK2 and approximately 30% reduction in a biomarker of LRRK2 activity in

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Thu, 21 May 2026 18:00:00 -0400

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints
Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 in idiopathic Parkinson’s disease
Denali continues to independently conduct the Phase 2a BEACON study in carriers of a pathogenic LRRK2 variant

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151),